Medifron DBT Co., Ltd. announced that it expects to receive KRW 4 billion in funding from Kiwoom Securities Co., Ltd., Investment Arm
September 12, 2021
Share
Medifron DBT Co., Ltd. announced a private placement of series 10 unregistered coupon non-guaranteed private convertible bond for gross proceeds of KRW 4,000,000,000 on September 13, 2021. The transaction will include participation from new investor Kiwoom Securities Co., Ltd., Investment Arm. The bonds carry 0% coupon rate, 2% yield to maturity, will mature on September 15, 2024, and are 100% convertible into 1,350,894 common shares of the company representing 3.10% stake, at a fixed conversion price of KRW 2,961 per share from September 15, 2022 till August 15, 2024. The subscription and payment date for the bonds is September 15, 2021. The transaction has been approved by the board of directors of the company. The bonds carry a hold period of one year.
Hyper Corporation Inc, formerly Medifron DBT Co Ltd, is a Korea-based company primarily engaged in the manufacture and sale of information and communication devices. The Company operates through three segments. The Information and Communication Technology Business segment is engaged in the manufacture and sale of gaming mice, gaming monitors, televisions, routers, and gaming devices. The Home Meal Replacement segment is engaged in the manufacture and supply of convenient meals. The New Drug Business segment is engaged in the development and sales of Alzheimer's treatments, non-narcotic painkillers, and early diagnosis kits for dementia.
HYPER CORPORATION INC. 
